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Arthritis pain? These 
supplements provide little relief 
Taken alone or together, these 2 supplements don’t 
relieve the pain of hip or knee osteoarthritis. 
Practice changer
Tell patients with large joint arthritis that glu-
cosamine and chondroitin have been found 
to be little better than placebo.1 
Wandel S, Juni P, Tendal B, et al.  Effects of glucosamine, chondroitin, 
or placebo in patients with osteoarthritis of hip or knee: network meta-
analysis.  BMJ .2010;314:c4675. 
Strength of recommendation 
a: Based on a good-quality meta-analysis. 
illustrative case
a 64-year-old woman with osteoarthritis (oa) 
of both knees reports that acetaminophen 
does not relieve the pain, and both ibupro-
fen and naproxen give her an upset stomach. 
She wonders if glucosamine and chondroitin 
would help relieve the pain. how should you 
respond? 
Degenerative joint disease is a com-mon and frustrating problem for patients and clinicians. Symptom-
atic knee OA has a prevalence of 16% among 
adults older than 45 years, and is one of the 
top 5 reasons for disability in noninstitution-
alized adults.2 With no highly effective treat-
ment for OA of the hip or knee other than 
joint replacement surgery, patients often turn 
to unproven over-the-counter remedies. In-
dividuals with OA spend about $2600 per year 
out-of-pocket on disease-related expenses.2 
trials of these supplements 
have had mixed results 
Glucosamine and chondroitin have been tout-
ed as beneficial, and sales have grown rapidly 
over the last decade, reaching nearly $900 mil-
lion in the United States in 2008 alone.3  There 
have been many randomized trials of these 
supplements, with  inconsistent results.
Larger and higher quality studies have 
found little or no effect, while smaller studies 
reported that glucosamine and chondroitin 
helped to relieve joint pain. A meta-analysis 
published in 2000 found 15 studies and re-
ported moderate to large effect sizes, but the 
authors noted that quality issues and publi-
cation bias probably exaggerated the ben-
efit.4  An updated Cochrane meta-analysis of 
25 randomized controlled trials (RCTs), pub-
lished in 2009, found little benefit from glu-
cosamine. A subgroup analysis found that 
one company’s preparation appeared to be 
beneficial, but all 14 studies of that particular 
formulation had some connection with the 
manufacturer.5 
study summary
Effects of glucosamine and chondroitin, 
alone or together, were small
The meta-analysis we review in this PURL 
only included RCTs with an average of ≥100 
patients with hip or knee OA in each group.1 
This was based on the minimum sample size 
needed to detect a small or moderate differ-
ence between the 2 groups (roughly 1 cm on 
a 10-cm visual analogue scale [VAS]). The 
authors found 10 eligible RCTs with a total of 
3803 patients; the average age of participants 
ranged from 58 to 66 years. Most of the trials 
studied knee arthritis, and most were spon-
sored by pharmaceutical firms. 
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Included studies had to compare glucos-
amine sulphate, glucosamine hydrochloride, 
chondroitin sulphate, or a combination, ei-
ther with a placebo or head-to-head.  Mini-
mum daily doses were 800 mg chondroitin 
and 1500 mg glucosamine. The primary out-
come was absolute pain intensity over the du-
ration of the study. The authors summarized 
pain scores every 3 months for up to 2 years; 
they also analyzed changes in joint space nar-
rowing in the studies reporting that measure. 
The authors used a sophisticated frame-
work that adjusted for comparisons over time 
and between studies, allowing them to in-
crease the power, and likely the accuracy, of 
their comparisons. They reported outcomes 
as effect sizes, then translated the findings to a 
real-world outcome by converting results to a 
10-cm VAS. Typically, an effect size of 0.2 stan-
dard deviation (SD) units is considered small, 
0.5 SD units is a moderate difference, and 0.8 
SD units is large. The authors set their thresh-
old for a clinically important difference at 0.37 
SD units, which translated to a 0.9 cm change 
on a 10-cm VAS—a generally accepted mini-
mal clinically significant difference in pain.  
They found that all 3 interventions (glu-
cosamine alone, chondroitin alone, and a 
combination) were statistically better than 
placebo, with very little difference in outcomes 
over time.  Compared with placebo, VAS im-
provements were 0.4 cm for glucosamine 
(95% confidence interval [CI], 0.1-0.7), 0.3 cm 
for chondroitin (95% CI, 0-0.7) and 0.5 cm for 
the combination (95% CI, 0-0.9).  All of these 
improvements in pain were less than the au-
thors’ defined minimum clinically significant 
improvement of 0.9 cm on a 10-cm scale.  
Among the 6 trials that reported on joint 
space narrowing, the changes were minute 
and not statistically significant. There was a 
net difference between treatment and place-
bo groups of less than 0.2 mm (an effect size 
≤0.16 SD units).  There was no evidence of 
increased risk of adverse effects or increased 
dropout rates with any of the substances.
What’s neW
Study results leave little room for doubt 
This meta-analysis used more sophisticated 
comparison techniques and used only larger 
(and probably better quality) studies than 
previous meta-analyses.  However, inclusion 
and exclusion were not based on any study 
quality criteria. 
The authors found that glucosamine 
and chondroitin, used alone or in combina-
tion, provide little benefit in terms of pain re-
lief of OA of the knee or hip compared with 
placebo, and contend that we should rec-
ommend against patients buying them. This 
meta-analysis is consistent with the Ameri-
can Academy of Orthopedic Surgeons 2008 
guideline for knee OA, which recommends 
not using glucosamine and/or chondroitin 
based on good evidence.6 
caveats
Rate of joint replacement  
was not considered
This meta-analysis did not study the effect of 
these supplements on joint replacement. In 
a 5-year follow-up study after completion of 
2 of the RCTs included in this meta-analysis, 
the relative risk of total joint replacement was 
0.43 (95% CI, 0.2-0.92) for those in the glucos-
amine group (who had taken 1500 mg glucos-
amine sulphate for 12-36 months) compared 
with placebo (NNT=12).7  However, the au-
thors were only able to follow up with 81% of 
the original participants. In the meta-analysis 
reported here, the difference in joint space 
narrowing was unlikely to be clinically signifi-
cant or to lead to a difference in joint replace-
ment rates.
Among the studies included in the meta-
analysis, commercially funded trials had a 
greater decrease in pain with glucosamine or 
chondroitin compared with independent tri-
als.  This did not change the overall outcome 
of the meta-analysis, thereby supporting the 
validity of the results.
challenges to imPlementation
these supplements are available otC
There are few barriers to advising patients 
not to use these products.  Since glucosamine 
and chondroitin are available over-the-coun-
ter, however, patients have ready access to 
them, even if their doctors don’t recommend 
them.  Several meta-analyses have not found 
Five years after 
completion of 
2 of the RCts 
included in the 
meta-analysis,  
the relative risk 
of total joint 
replacement was 
0.43 for those in 
the glucosamine 
group compared 
with placebo. 
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an increased risk of harm from these prod-
ucts (other than the expense).1,5               JFP
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•   Assessing asthma severity
•   Ensuring treatment adherence and setting goals
•   The role of inflammation and air trapping in 
treatment delivery
•   When and how to step up therapy
•   When to add a long-acting b-agonist (LABA)
•   Communication strategies for better patient 
self-management, better asthma control
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